NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · page 17 of 33
The slide highlights a 37.4% reduction in disease progression with statistical significance (p=0.03) in the per-protocol population, while noting a 29% reduction in the ITT analysis.
Pitch deck · traction · show_traction · balanced density
Slide locked Sign in to view
Slide schematic 5/5
chart 1/1 disclaimer 1/1 source-note 1/1 title 2/2
Components 5
line disclaimer source-note action-title headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.